Symphogen: Big shoes to fill
Copenhagen-based Symphogen is losing its long-time CEO Kirsten Drejer, who co-founded the Danish antibody specialist in 2000. In her place, erstwhile CFO Martin Olin is taking over the helm.
Before joining Symphogen in 2012 as CFO, Olin served as Investment Director at Scandinavian Life Science Invest. Prior to that, he was partner at Medicon Valley Capital and Finance Director, EMEA for Novo Nordisk. Olin serves as director on the board of several life science companies, among them Gyros, Light Sciences Oncology, and Precisense. Drejer, on her end, will remain on board of the company as Executive Director.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium